Eddie Pan

Eddie Pan

Expertise: Institutional Investments, Insider Activity, Disruptive Innovations

Education: BBA, Finance, James Madison University

About Eddie:
Eddie Pan specializes in institutional investments and insider activity. He has been enamored with hedge funds since he began investing and regularly collaborates with industry executives to craft editorial pieces. Tracking the investments of institutional investors and insiders can provide a vast array of knowledge that is scarcely covered.

After receiving his BBA in Finance from James Madison University, Eddie began his career at Accenture as an analyst. Today, he writes for InvestorPlace’s Today’s Market team, which centers on the latest news involving popular stocks.

Eddie got his start in the financial media world by publishing articles on top-performing hedge funds and their investment strategies on Substack. He still publishes pieces on his Substack today.

Common Stocks and Uncommon Profits by Philip A. Fisher is Eddie’s favorite investment book. Fisher’s 15 Points have heavily influenced his investment strategy.

Recent Articles

Why Are Stocks Down Today? 4 Things to Know.

Why are stocks down today? It seems that fears over tapering, inflation and the omicron variant are worrying investors on Tuesday.

GBS Stock: The Covid Antibody Test News Shooting GBS Shares Higher Today

Shares of GBS stock are trading higher after a clinical study at Harvard University yielded positive results for the company's antibody test.

Saitama Price Predictions: How High Can an Altcoin Rally Take the SAITAMA Crypto?

Saitama has rallied this past week after declining on a warning announcement. Could it go higher? Let's look at Saitama price predictions.

PPSI Stock: 14 Things to Know as Pioneer Power Squeezes 50% Higher

PPSI stock is accelerating higher today on elevated volume. Here's what investors need to know about the company as it squeezes higher.

ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential

Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant.